Current Testing Methods and Challenges for Detection of Adventitious Viruses

References

1. 1.↵
   1. Khan A. S.

   Regulatory considerations for raw materials used in biological products. PDA J. Pharm. Sci. Technol. 2010, 64 (5), 451–457.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   Center for Biologics Evaluation and Research (CBER). Points to consider in the characterization of cell lines used to produce biologicals. U.S. Food and Drug Administration (FDA): Rockville, MD, July 1993.
3. 3.↵
   CBER. Points to consider in the manufacture and testing of therapeutic products for human use derived from transgenic animals. U.S. FDA: Rockville, MD, January 1995.
4. 4.↵
   CBER. Points to consider in the manufacture and testing of monoclonal antibody products for human use. U.S. FDA: Rockville, MD, February 1997.
5. 5.↵
   CBER. Guidance for industry: Source animal, product, preclinical, and clinical issues concerning the use of xenotransplantation products in humans. U.S. FDA: Rockville, MD, April 2003.
6. 6.↵
   CBER. Guidance for industry: Supplemental guidance on testing for replication competent retrovirus in retroviral vector based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors. U.S. FDA: Rockville, MD, November 2006.
7. 7.↵
   Code of Federal Regulations, Title 9, Animal and Animal Products (current year): Part 113.53, Requirements for ingredients of animal origin used for production of biologics. Office of the Federal Register, National Archives and Records Administration, U.S. Government Printing Office: Washington DC. January 1, 2011.
8. 8.↵
   CBER. Guidance for industry: Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. U.S. FDA: Rockville, MD, Rockville, MD; February 2010.
9. 9.↵
   Code of Federal Regulations, Title 21, Part 610. Food and Drugs, General Biological Products Standards. Office of the Federal Register, National Archives and Records Administration, U.S. Government Printing Office: Washington, DC, April 1, 2009.
10. 10.↵
    International Conference on Harmonization. ICH Topics Q5D—Guidance on derivation and characterization of cell substrates used for production of biotechnological/biological products. 21 Sept 1998.
11. 11.↵
    International Conference on Harmonisation. ICH Topics Q5A(R1)—Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. 23 Sept 1999.
12. 12.↵
    World Health Organization (WHO). WHO Expert Committee on Biological Standardization, 47th Report: Requirements for the use of animal cells as in vitro substrates for the production of biologicals. WHO Technical Report Series, No. 878, Annex 1, 1998.
13. 13.↵
    1. Khan A. S.

    Characterization and qualification of cell substrates for manufacturing viral vaccines in the United States. BioProcessing J. 2009, 8 (3), 8–12.

    OpenUrl
14. 14.↵
    1. Khan A. S.

    Testing considerations for novel cell substrates: a regulatory perspective. PDA J. Pharm. Sci. Technol. 2010, 64 (5), 426–431.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Ma H.,
    2. Ma Y.,
    3. Ma W.,
    4. Williams D. K.,
    5. Galvin T. A.,
    6. Khan A. S.

    Chemical induction of endogenous retrovirus particles from the Vero cell line of African green monkeys. J. Virol. 2011, 85 (13), 6579–6588.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Ma W.,
    2. Galvin T. A.,
    3. Ma H.,
    4. Muller J.,
    5. Khan A. S.

    Optimization of chemical induction conditions for human herpesvirus 8 (HHV-8) reactivation with 12-O-tetradecanoyl-phorbol-13-acetate (TPA) from latently-infected BC-3 cells. Biologicals 2011, 39 (3), 158–166.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Onions D.,
    2. Côté C.,
    3. Love B.,
    4. Toms B.,
    5. Koduri S.,
    6. Armstrong A.,
    7. Chang A.,
    8. Kolman J.

    Ensuring the safety of vaccine cell substrates by massively parallel sequencing of the transcriptome. Vaccine 2011 Jun 7 [Epub ahead of print].
18. 18.↵
    1. Ecker D. J.,
    2. Sampath R.,
    3. Massire C.,
    4. Blyn L. B.,
    5. Hall T. A.,
    6. Eshoo M. W.,
    7. Hofstadler S. A.

    Ibis T5000: a universal biosensor approach for microbiology. Nat. Rev. Microbiol. 2008, 6 (7), 553–558.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Tang P.,
    2. Chen C.

    Metagenomics for the discovery of novel human viruses. Future Microbiol. 2010, 5 (2), 177–189.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Gardner S. N.,
    2. Jaing C. J.,
    3. McLoughlin K. S.,
    4. Slezak T. R.

    A microbial detection array (MDA) for viral and bacterial detection. BMC Genomics 2010, 11 (1), 668.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Onions D.,
    2. Kolman J.

    Massively parallel sequencing, a new method for detecting adventitious agents. Biologicals 2010, 38 (3), 377–380.

    OpenUrlPubMed